Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CPA1 | P15085 | 3/20 | 0.35 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.35 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7680206 | 0.92 | PPARD (0.39) | ALDH1A1MEN1KMT2ACYP3A4CPA1 | |
| SCHEMBL7684336 | 0.85 | ALDH1A1 (0.40) | ALDH1A1CYP3A4CPA1MAPTSMN1; SMN2 | |
| SCHEMBL7687237 | 0.85 | CNR1 (0.43) | ALDH1A1CYP3A4CPA1MAPTNPSR1 | |
| SCHEMBL6492632 | 0.84 | ALDH1A1 (0.40) | ALDH1A1CYP3A4CPA1MAPTNPSR1 | |
| SCHEMBL6477248 | 0.84 | CYP2C9 (0.45) | ALDH1A1KMT2ACYP3A4CPA1MAPT | |
| SCHEMBL121197 | 0.84 | ALDH1A1 (0.40) | ALDH1A1MEN1KMT2ACYP3A4CPA1 | |
| SCHEMBL6487215 | 0.84 | ALDH1A1 (0.42) | ALDH1A1CYP3A4CPA1 | |
| SCHEMBL7686449 | 0.82 | CYP2C19 (0.41) | ALDH1A1MEN1KMT2AMAPTNPSR1 | |
| SCHEMBL6479508 | 0.82 | ALDH1A1 (0.38) | ALDH1A1MEN1KMT2ACYP3A4MAPT | |
| SCHEMBL7689051 | 0.81 | CNR1 (0.42) | ALDH1A1MEN1KMT2ACYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6861530-B2 | Piperidine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-03-01 | — | — | US | disclosed |
| US-6492392-B1 | INHIBITING TUMOR CELL PROLIFERATION | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-12-10 | — | — | US | disclosed |
| US-20020137770-A1 | Piperidine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-09-26 | — | — | US | disclosed |
| WO-2001085716-A1 | 2-PIPERIDONE COMPOUNDS FOR THE TREATMENT OF CANCER | KYOWA HAKKO KOGYO CO., LTD (JP) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137770-A1 | Piperidine derivatives | CIP2A, PARP2, TP53 | ALDH1A1 270/4885MEN1 1991/4885KMT2A 1289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.